TG Therapeutics is committed to the development of innovative therapeutic products that extend and enhance the quality of life for patients suffering from cancer and other underserved therapeutic needs. An integral part of achieving this goal is the conduct of robust and efficient clinical trials at the highest standards of quality attainable.
Information on TG Therapeutics' ongoing clinical trials, including information for healthcare providers and patients interested in participating in any ongoing clinical trials, can be found at www.clinicaltrials.gov.
Please use the below links for our ongoing Phase 3 & Phase 2b Trials:
NOW ENROLLING THE PHASE 3 UNITY-CLL TRIAL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (UNITY-CLL)
NOW ENROLLING THE PHASE 2b UNITY-DLBCL TRIAL: Ublituximab + TGR-1202 Compared to TGR-1202 in Patients With Diffuse Large B-Cell Lymphoma (UNITY-DLBCL)
THE GENUINE PHASE 3 TRIAL (ONGOING, BUT NO LONGER RECRUITING PATIENTS): Ublituximab in Combination with Ibrutinib Versus Ibrutinib Alone in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)